- ELND005: small molecule drug to enter Phase 3 for the treatment of Alzheimer's disease
- TT401/TT402: long-acting GLP-1 dual agonists for type 2 diabetes that provide glycemic control, weight management, improved lipid profile and better GI tolerability
- TT301/TT302: novel orally bioavailable aminopyridizines for rheumatoid arthritis, that inhibit multiple pro-inflammatory cytokines and chemokines
Transition’s diabetes compounds TT401/402, brought in through a partnership with Eli Lilly, simultaneously address both glycemic control and weight reduction. TT401/TT402 are long-acting GLP-1 dual agonists that address multiple unmet medical needs by offering glycemic control, superior weight management and improved lipid profile, plus better GI tolerability as compared to current GLP-1 drugs. Furthermore, these compounds are being developed as once weekly administrations, a major dosing advantage over currently approved injectable GLP-1 therapies that are dosing once or twice daily. Phase 1-enabling preclinical studies are currently underway, with initiation of Phase 1 targeted for 4Q 2011. Also included in the report is a complete background of Transition’s programs, preclinical and clinical history to date, upcoming expected milestones, product positioning in the markets, and associated risks.Dr. McDonald’s full Initiation Report is available to download at no cost at the LifeSci Advisors website, www.lifesciadvisors.com. In addition to this Initiation Report, LifeSci Advisors will also provide ongoing coverage and event-based research updates on the Company as developments occur. The LifeSci Advisors research team is led by Dr. Andrew I. McDonald, an industry veteran with more than 15 years of healthcare industry experience. Prior to co-founding LSA, Dr. McDonald was the Senior Biotechnology Analyst at Great Point Partners, a leading health care investment firm with over $500 million under management. Before Great Point, he was Co-head of Healthcare Research and Lead Biotechnology Analyst at ThinkEquity Partners, a boutique investment banking firm focused on growth companies. Dr. McDonald holds a Ph.D. in organic chemistry from the University of California, Irvine, and, earlier in his career, worked as a medicinal chemist at both Pfizer and Cytokinetics. About LifeSci Advisors: LifeSci Advisors (LSA) is a leading research firm and communications consultancy dedicated to the life sciences industry. The firm provides strategic counsel, customized marketing communications, comprehensive research reports and investor relations services to companies that specialize in the discovery, development and commercialization of drugs, drug delivery systems, medical devices and diagnostics. To learn more about LSA, visit the company’s website, www.lifesciadvisors.com. Important Disclosures : The research report described in this press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell securities. The securities discussed in LSA research reports may be unsuitable for some investors depending on their specific investment objectives, financial status, risk profile, or particular needs. Investors should consider LSA reports as only a single factor in making their investment decisions and should not rely solely on these reports in evaluating whether or not to buy or sell the securities of the subject company. LifeSci Advisors has been compensated by the company that is the subject of the report described and future research reports, investor relations services, and general consulting services. Please read each report's full disclosures and analyst background on the LSA website, www.lifesciadvisors.com, before investing. LifeSci Advisors is not a registered investment adviser or broker-dealer. Forward-looking statements: This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. These forward-looking statements represent LSA's judgment as of the date of this release. LifeSci Advisors disclaims, however, any intent or obligation to update these forward-looking statements.